Maia Pharms Inc Company Profile

✉ Email this page to a colleague

MAIA PHARMS INC has nine approved drugs.

There are seven US patents protecting MAIA PHARMS INC drugs.

There are four patent family members on MAIA PHARMS INC drugs in three countries and seventy-two supplementary protection certificates in nine countries.

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Maia Pharms Inc	SODIUM PHENYLACETATE AND SODIUM BENZOATE	sodium benzoate; sodium phenylacetate	SOLUTION;INTRAVENOUS	215025-001	Jun 10, 2021	AP	RX	Yes	Yes		⤷ Try a Trial				⤷ Try a Trial
Maia Pharms Inc	BACLOFEN	baclofen	INJECTABLE;INTRATHECAL	210777-001	Jan 15, 2021	AP	RX	No	No		⤷ Try a Trial				⤷ Try a Trial
Maia Pharms Inc	SINCALIDE	sincalide	POWDER;INTRAVENOUS	210850-001	Nov 22, 2022		RX	Yes	Yes	11,110,063	⤷ Try a Trial	Y			⤷ Try a Trial
Maia Pharms Inc	BORTEZOMIB	bortezomib	SOLUTION;INTRAVENOUS	215331-002	Jul 27, 2022		DISCN	Yes	No	11,679,119	⤷ Try a Trial				⤷ Try a Trial
Maia Pharms Inc	ANGIOMAX RTU	bivalirudin	SOLUTION;INTRAVENOUS	211215-001	Jul 25, 2019		RX	Yes	Yes	11,918,622	⤷ Try a Trial				⤷ Try a Trial
Maia Pharms Inc	LEVOTHYROXINE SODIUM	levothyroxine sodium	POWDER;INTRAVENOUS	208749-002	Dec 21, 2018	AP	RX	No	No		⤷ Try a Trial				⤷ Try a Trial
Maia Pharms Inc	LEVOTHYROXINE SODIUM	levothyroxine sodium	POWDER;INTRAVENOUS	208749-001	Dec 21, 2018	AP	RX	No	No		⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	for Injection	200 mcg/vial	➤ Subscribe	2015-05-01
➤ Subscribe	for Injection	100 mcg/vial and 500 mcg/vial	➤ Subscribe	2015-04-14

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration
Canada	3073944	⤷ Try a Trial
European Patent Office	3672616	⤷ Try a Trial
World Intellectual Property Organization (WIPO)	2019040904	⤷ Try a Trial
World Intellectual Property Organization (WIPO)	2023049346	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2822954	SPC/GB18/031	United Kingdom	⤷ Try a Trial	PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM.; REGISTERED: UK EU/1/18/1289/001(NI) 20180625; UK EU/1/18/1289/002(NI) 20180625; UK PLGB 11972/0008 20180625
2932970	1890039-9	Sweden	⤷ Try a Trial	PRODUCT NAME: DOLUTEGRAVIR SODIUM + RILPIVIRINE HYDROCHLORIDE; REG. NO/DATE: EU/1/18/1282 20180518
2380576	20C1048	France	⤷ Try a Trial	PRODUCT NAME: SEL DE SODIUM DE L'ACIDE DESOXYCHOLIQUE; NAT. REGISTRATION NO/DATE: NL46299 20180810; FIRST REGISTRATION: IS - IS/1/16/071/01 20160729
0579826	02C0041	France	⤷ Try a Trial	PRODUCT NAME: ERTAPENEM SODIUM; REGISTRATION NO/DATE: EU/1/02/216/001 20020418
1874117	SPC/GB14/041	United Kingdom	⤷ Try a Trial	PRODUCT NAME: DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING DOLUTEGRAVIR SODIUM; REGISTERED: UK EU/1/13/892/001-006 20140121
1758590	LUC00029	Luxembourg	⤷ Try a Trial	PRODUCT NAME: SEL DE SODIUM D'ACIDE DEOXYCHOLIQUE; AUTHORISATION NUMBER AND DATE: IS/1/16/071/01 20170401
2822954	1890030-8	Sweden	⤷ Try a Trial	PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; REG. NO/DATE: EU/1/18/1289 20180625
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.